Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label attachment file name title
tabling member	label

Search

1684148

	registered interest
	date	22/01/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Social Work: Staff
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps her Department is taking to tackle social work workforce (a) shortages and (b) recruitment.
	tabling member constituency	Bolton West
	tabling member printed	Chris Green
	uin	10832
	answer	answer is ministerial correction date of answer 30/01/2024 answer text <p>We recognise and value the vital contribution of regulated professions, including social workers in adult social care, and are committed to developing the skills of the workforce. That is why we announced a new fund on 10 January 2024 to support recruitment of social work apprentices into adult social care over the next three years.</p><p> </p><p>The new funding will allow local authorities to apply for a contribution towards the costs of training and supervising new social work apprenticeships. Details on what the funding can be used for, how to access the funding, and employer eligibility will be set out in guidance to be published on GOV.UK shortly.</p> answering member constituency Faversham and Mid Kent answering member printed Helen Whately question first answered 30/01/2024 09:16:23 answering member 4527 label Biography information for Helen Whately
	tabling member	4398 label Biography information for Chris Green

1684146

	registered interest
	date	22/01/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Carers: Older People
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, with reference to the report entitled The Impact of Care Act Easements published by the University of Manchester and the NIHR Older People and Frailty Policy Research Unit in November 2022, what steps her Department is taking to support local authorities in identifying hidden older carers within their communities.
	tabling member constituency	Bolton West
	tabling member printed	Chris Green
	uin	10831
	answer	answer is ministerial correction date of answer 30/01/2024 answer text <p>Under the Care Act 2014, local authorities are required to undertake a Carer’s Assessment for any unpaid carer who appears to have need for support, and to meet their eligible needs upon request from the carer.</p><p> </p><p>On 24 October 2023, the adult social care’s Innovation and Improvement Unit launched the Accelerating Reform Fund which provides a total of £42.6 million over 2023/24 and 2024/25 to support innovation and scaling in adult social care, and to kick start a change in services to support unpaid carers. The list of priorities for innovation and scaling includes focussing on identifying unpaid carers in local areas, encouraging people to recognise themselves as carers, and promoting access to carer services.</p><p> </p><p>The adult social care reform white paper, People at the Heart of Care, published on 1 December 2021, highlighted the potential to increase the voluntary use of unpaid carer markers in National Health Service electronic health records. In 2022, NHS England wrote to all general practices about the importance of identifying carers and advising how caring status should be recorded on patient records.</p> answering member constituency Faversham and Mid Kent answering member printed Helen Whately question first answered 30/01/2024 09:13:05 answering member 4527 label Biography information for Helen Whately
	tabling member	4398 label Biography information for Chris Green

1672319

	registered interest
	date	22/11/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Rare Diseases: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, with reference to the Answer of 20 October 2023 to Question 202779 on Rare Diseases: Drugs, how many single technology appraisals of medicines conducted by the National Institute for Health and Care Excellence for non-orphan medicines resulted in (a) a positive recommendation, (b) an optimised recommendation, (c) a recommendation for managed access, (d) a negative recommendation and (e) termination in each financial year since 2018-19.
	tabling member constituency	Bolton West
	tabling member printed	Chris Green
	uin	3244
	answer	answer is ministerial correction date of answer 28/11/2023 answer text <p>The information requested is provided in the attached table.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 28/11/2023 12:58:08 answering member 4044 label Biography information for Andrew Stephenson attachment 1 file name FORMATTED TABLE FOR MINISTERIAL CLEARANCE PQ3244.docx title Rare Diseases
	tabling member	4398 label Biography information for Chris Green

1665087

	registered interest
	date	16/10/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Rare Diseases: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how many highly specialised technology evaluations of medicines for very rare diseases conducted by the National Institute for Health and Care Excellence resulted in (a) a positive recommendation, (b) an optimised recommendation, (c) a recommendation for managed access, (d) a negative recommendation and (e) termination in each financial year since 2018-19.
	tabling member constituency	Bolton West
	tabling member printed	Chris Green
	uin	202780
	answer	answer is ministerial correction date of answer 20/10/2023 answer text <p>The following table shows a breakdown of technologies appraised through the National Institute for Health and Care Excellence’s highly specialised technology process by financial year from 2018/19:</p><p> </p><table><tbody><tr><td><p>Financial Year</p></td><td><p>2018/19</p></td><td><p>2019/20</p></td><td><p>2020/21</p></td><td><p>2021/22</p></td><td><p>2022/23</p></td><td><p>Total</p></td></tr><tr><td><p>Recommended</p></td><td><p>1</p></td><td><p>4</p></td><td><p>2</p></td><td><p>4</p></td><td><p>4</p></td><td><p>15</p></td></tr><tr><td><p>Optimised</p></td><td><p>0</p></td><td><p>0</p></td><td><p>0</p></td><td><p>0</p></td><td><p>1</p></td><td><p>1</p></td></tr><tr><td><p>Not recommended</p></td><td><p>0</p></td><td><p>0</p></td><td><p>0</p></td><td><p>0</p></td><td><p>0</p></td><td><p>0</p></td></tr><tr><td><p>Total</p></td><td><p>1</p></td><td><p>4</p></td><td><p>2</p></td><td><p>4</p></td><td><p>5</p></td><td><p>16</p></td></tr><tr><td><p>Terminated</p></td><td><p>0</p></td><td><p>0</p></td><td><p>0</p></td><td><p>0</p></td><td><p>0</p></td><td><p>0</p></td></tr></tbody></table> answering member constituency Colchester answering member printed Will Quince question first answered 20/10/2023 11:26:24 answering member 4423 label Biography information for Will Quince
	tabling member	4398 label Biography information for Chris Green

1665086

	registered interest
	date	16/10/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Rare Diseases: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how many single technology appraisals for medicines for rare diseases conducted by the National Institute for Health and Care Excellence resulted in (a) a positive recommendation, (b) an optimised recommendation, (c) a recommendation for managed access, (d) a negative recommendation and (e) termination in each financial year since 2018-19.
	tabling member constituency	Bolton West
	tabling member printed	Chris Green
	uin	202779
	answer	answer is ministerial correction date of answer 20/10/2023 answer text <p>The following table shows a breakdown of technologies with designated orphan status appraised through the National Institute for Health and Care Excellence resulted single technology appraisal process by financial year from 2018/19:</p><p> </p><table><tbody><tr><td><p>Financial Year</p></td><td><p>2018/19</p></td><td><p>2019/20</p></td><td><p>2020/21</p></td><td><p>2021/22</p></td><td><p>2022/23</p></td><td><p>Total</p></td></tr><tr><td><p>Recommended</p></td><td><p>2</p></td><td><p>1</p></td><td><p>6</p></td><td><p>11</p></td><td><p>5</p></td><td><p>25</p></td></tr><tr><td><p>Recommended (Cancer Drugs Fund)</p></td><td><p>2</p></td><td><p>2</p></td><td><p>4</p></td><td><p>0</p></td><td><p>0</p></td><td><p>8</p></td></tr><tr><td><p>Optimised</p></td><td><p>3</p></td><td><p>9</p></td><td><p>3</p></td><td><p>3</p></td><td><p>8</p></td><td><p>26</p></td></tr><tr><td><p>Optimised (Cancer Drugs Fund)</p></td><td><p>1</p></td><td><p>1</p></td><td><p>0</p></td><td><p>1</p></td><td><p>0</p></td><td><p>3</p></td></tr><tr><td><p>Research Only</p></td><td><p>0</p></td><td><p>0</p></td><td><p>0</p></td><td><p>0</p></td><td><p>0</p></td><td><p>0</p></td></tr><tr><td><p>Not Recommended</p></td><td><p>2</p></td><td><p>0</p></td><td><p>0</p></td><td><p>1</p></td><td><p>2</p></td><td><p>5</p></td></tr><tr><td><p>Total</p></td><td><p>10</p></td><td><p>13</p></td><td><p>13</p></td><td><p>16</p></td><td><p>15</p></td><td><p>67</p></td></tr><tr><td><p>Terminated</p></td><td><p>1</p></td><td><p>5</p></td><td><p>5</p></td><td><p>10</p></td><td><p>2</p></td><td><p>23</p></td></tr></tbody></table><p> </p><p>Medicines with an orphan designation are for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition that is rare, namely affecting not more than five in 10,000 people in Great Britain, or where the medicine is unlikely to generate sufficient profit to justify research and development costs.</p> answering member constituency Colchester answering member printed Will Quince question first answered 20/10/2023 11:24:13 answering member 4423 label Biography information for Will Quince
	tabling member	4398 label Biography information for Chris Green

1665090

	registered interest
	date	16/10/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Rare Diseases: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether the National Institute for Health and Care Excellence has made an assessment of the potential merits of undertaking modular updates on topics relevant to rare diseases since the publication of its updated process and methods for health technology evaluation on 31 January 2022.
	tabling member constituency	Bolton West
	tabling member printed	Chris Green
	uin	202783
	answer	answer is ministerial correction date of answer 19/10/2023 answer text <p>The National Institute for Health and Care Excellence (NICE) has no current plans to undertake a modular update of its methods and processes related specifically to rare diseases. NICE specifically considered treatments for rare diseases during its methods review, and many of the changes introduced in NICE’s updated health technology evaluation manual in January 2022 will benefit treatments for rare diseases. These include the severity modifier, flexibility in uncertainty considerations and the emphasis on a comprehensive evidence base including real-world, qualitative, surrogate, and expert evidence. These updates mitigate the barriers faced by rare disease technologies while maintaining an evidence-based, robust, and proportionate evaluation approach.</p> answering member constituency Colchester answering member printed Will Quince question first answered 19/10/2023 16:20:56 answering member 4423 label Biography information for Will Quince
	tabling member	4398 label Biography information for Chris Green

1655862

	registered interest
	date	01/09/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Influenza: Vaccination
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether his Department makes an estimate of the timescale for manufacturing influenza vaccines to (a) inform its decision on eligibility for the annual NHS influenza immunisation programme and (b) ensure the adequacy of supply of those vaccines across the country.
	tabling member constituency	Bolton West
	tabling member printed	Chris Green
	uin	195971
	answer	answer is ministerial correction date of answer 14/09/2023 answer text <p>The Joint Committee on Vaccination and Immunisation regularly discuss with the vaccine manufacturing industry issues such as the availability of new and existing vaccines, and manufacturing lead in times. Their advice about which flu vaccines are to be used for the coming season is informed by these discussions. An effective programme depends on a reliable supply of vaccine. It takes approximately five to six months for the first supplies of approved vaccine to become available once a new strain of influenza virus is identified and isolated.</p><p>National Health Service providers determine how many seasonal flu vaccines to buy for eligible cohorts each year based on their local populations, as outlined in the annual flu system letter. The letter, published on 25 May 2023, is based on the advice of the JCVI, which reviews the latest evidence on flu vaccines and advises on the type of vaccine to be offered to different age groups and on which vaccines should be prioritised for various at-risk groups.</p><p>General practitioners and community pharmacists are responsible for ordering their own flu vaccines for the adult population from suppliers. These are then used to deliver the national flu vaccination programme, with deliveries phased through the season to help mitigate against risks of wastage, cold chain failure and to adequately cover the peaks and flows of local demand.</p><p>NHS England encourages their contractors to purchase vaccines from more than one manufacturer to mitigate against the risk of supply issues. Regional NHS England commissioners, in partnership with their local systems, also make assessments of the amount of vaccine available in their area to ensure there is enough supply to meet public demand.</p><p>The UK Health Security Agency secures and supplies a sufficient volume of flu vaccines used in the children’s flu programme to ensure that eligible children aged less than 18 years old who present for vaccination can be offered an appropriate vaccine.</p> answering member constituency Lewes answering member printed Maria Caulfield question first answered 14/09/2023 15:27:31 answering member 4492 label Biography information for Maria Caulfield
	tabling member	4398 label Biography information for Chris Green

1655863

	registered interest
	date	01/09/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Influenza: Vaccination
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether his Department plans to ask the Joint Committee on Vaccination and Immunisation to update the baseline modelling and assumptions it uses to make decisions on the cost-effectiveness of vaccinating specific age cohorts against seasonal influenza.
	tabling member constituency	Bolton West
	tabling member printed	Chris Green
	uin	195972
	answer	answer is ministerial correction date of answer 08/09/2023 answer text <p>For the Joint Committee on Vaccination and Immunisation to formally revisit the cost-effectiveness of vaccinating specific age cohorts against seasonal influenza, an up-to-date impact and cost effectiveness analysis would be required, and the UK Health Security Agency is in the process of updating the influenza model using more recent data, including accounting for changes due to the pandemic.</p><p>There is currently uncertainty on any longer-term changes because of the pandemic to social contact patterns and the activity of flu in the population for a fully robust update to cost effectiveness analysis in the short term.</p> answering member constituency Lewes answering member printed Maria Caulfield question first answered 08/09/2023 14:16:55 answering member 4492 label Biography information for Maria Caulfield
	tabling member	4398 label Biography information for Chris Green

1655861

	registered interest
	date	01/09/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Gene Therapies
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 11 July 2023 to Question 192548 on Gene Therapies, how many of the advanced therapeutic medicinal products evaluated by the National Institute for Health and Care Excellence that have been recommended for use were gene therapies appraised through the Single Technology Appraisal pathway.
	tabling member constituency	Bolton West
	tabling member printed	Chris Green
	uin	195970
	answer	answer is ministerial correction date of answer 08/09/2023 answer text <p>As of 5 September 2023, the National Institute for Health and Care Excellence has made positive recommendations on eight out of the nine gene therapy medicinal products it has evaluated using its single technology appraisal process.</p> answering member constituency Colchester answering member printed Will Quince question first answered 08/09/2023 12:02:28 answering member 4423 label Biography information for Will Quince
	tabling member	4398 label Biography information for Chris Green

1655857

	registered interest
	date	01/09/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, with reference to his Department's document entitled Final impact assessment: statutory scheme to control costs of branded health service medicines, published in March 2020, whether his Department plans to update that impact assessment using data from the Life Sciences Competitiveness Indicators 2023.
	tabling member constituency	Bolton West
	tabling member printed	Chris Green
	uin	195966
	answer	answer is ministerial correction date of answer 07/09/2023 answer text <p>The Government publishes new impact assessments each time the statutory scheme is updated. Further impact assessments were published in respect of updates made to the statutory scheme in 2022 and 2023.</p><p>The Government is currently consulting on updates to the statutory scheme to make sure that the scheme can continue to meet its objectives from 2024 onwards. A consultation stage impact assessment of the proposed updates has been published, and is available at the following link:</p><p><a href="https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1179564/impact-assessment-review-scheme-cost-branded-medicines-updated-21-august-2023.pdf" target="_blank">https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1179564/impact-assessment-review-scheme-cost-branded-medicines-updated-21-august-2023.pdf</a></p><p>An updated impact assessment will be published alongside the response to the consultation and will include the updated Competitiveness Indicators in the evidence base.</p> answering member constituency Colchester answering member printed Will Quince question first answered 07/09/2023 15:02:04 answering member 4423 label Biography information for Will Quince
	tabling member	4398 label Biography information for Chris Green